Spina Bifida Specialist Joins Dignify Therapeutics’ Clinical Scientific Advisory Board

RESEARCH TRIANGLE PARK, N.C.--Dignify Therapeutics, LLC, announced that Dr. Bradley P. Kropp, MD, FAAP, FACS has joined Dignify’s scientific advisory board. Dr. Kropp is Chief of the Pediatric Urology Service at the Children’s Hospital and Professor of Urology at Oklahoma University Health Science Center.  He is past-President of the Society of Fetal Urology and the American Association of Pediatric Urology.  He is a member of the American Academy of Pediatrics and the Society for Pediatric Urology.

 “Dignify Therapeutics is extremely excited to have Dr. Kropp join us to provide therapy for  voiding function for people with spina bifida,” said Dr. Karl Thor, President, Dignify Therapeutics.  “Interestingly, Dr. Kropp conducted research on use of intestinal submucosa as a scaffold for bladder regeneration while working in my laboratory at Eli Lilly and Company during his fellowship training at Indiana University Hospital in the 1990s.  I was, and continue to be, impressed with his ability to apply sophisticated scientific principles to clinical research.”

>>Why isn't this article about your business? Publicity and branding solutions from Innovative Public Relations<<

“I have been following the scientific research of Dignify Therapeutics’ scientists since my medical school days.  I am highly enthusiastic about joining Dr. Kennelly and Dr. Alexander on the Scientific Advisory Board and advancing Dignify’s discoveries from the lab and into the clinic,” said Dr. Kropp.   “Dealing with voiding dysfunction can be a substantial lifetime burden for people born with spina bifida.  A safe, effective, and convenient ‘on-demand’ therapy to induce voiding would obviously be a welcome therapeutic option.”

About Dignify Therapeutics LLC

Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics' mission is to provide safe and effective, practical and convenient, “on-demand”pharmaceutical agents to treat bladder and bowel voiding dysfunctions, using a “repositioning”strategy of drug discovery that the team has successfully implemented multiple times over the last 20 years in the fields of urology and gastroenterology.